Bacteria worldwide keep developing new resistances to antibiotics. Alternative therapies are urgently needed to meet this challenge. To this end, the Fraunhofer Institute for Toxicology and Experimental Medicine ITEM, Leibniz Institute DSMZ-German Collection of Microorganisms and Cell Cultures, Charité – Universitätsmedizin Berlin, and Charité Research Organisation have teamed up and initiated the project “Phage4Cure”. The goal is to establish bacteriophages as an approved drug for treating bacterial infections. The German Federal Ministry of Education and Research is funding this project with almost four million euros over a period of three years.
The aim of the German research project “Phage4Cure” is to establish bacteriophages as an approved drug in the fight against infection. Bacteriophages are viruses that highly specifically recognize and bind to a certain type of bacteria, eventually causing their destruction. I
n eastern Europe in particular, phages have been successfully used for decades already as an alternative or complementary treatment to traditional antibiotic therapy. In the European Union, however, they have not yet been approved as drugs.
This is due, among other reasons, to missing quality standards for bacteriophage production, a sine qua non for drug approval by the authorities. Furthermore, systematic clinical trials first have to be performed to demonstrate the safety, tolerability, and efficacy of treatment with phages. This is exactly the aim the project partners are now going for.
The scientists will explore bacteriophages specifically targeting the bacterium Pseudomonas aeruginosa. This bacterium frequently becomes multiresistant and can cause, for example, lung infections. “Our goal in the medium term is to develop phages as a medicinal product that can be delivered via different routes of administration, to provide a novel and additional therapeutic option for different infectious diseases – in particular for those cases where antibiotics have reached their limits,” says Dr. Holger Ziehr, project coordinator and director of the Fraunhofer ITEM Division of Pharmaceutical Biotechnology.
In the project “Phage4Cure”, the four partners with their special know-how are each working on a different aspect of this topic. The Leibniz Institute DSMZ working group under Dr. Christine Rohde will identify bacteriophages targeting Pseudomonas aeruginosa, including genetic characterization.
“There are many different Pseudomonas aeruginosa strains, with only minor differences between them. The challenge is to identify phages with as broad a spectrum of hosts as possible,” the scientist explains. The phages will then be passed on to Fraunhofer ITEM for further high-quality purification and pharmacological production.
The Fraunhofer team under Dr. Holger Ziehr will develop a so-called platform manufacturing process for phage-based therapeutic agents. This means that the manufacturing process can subsequently be used for other phages as well. In addition, the Fraunhofer ITEM scientists will perform preclinical testing.
Further preclinical tests will be conducted at Charité – Universitätsmedizin Berlin by scientists from the team of Professor Martin Witzenrath, Deputy Director of the Medical Department, Division of Infectiology and Pneumonology. Professor Witzenrath is also involved in the design, planning, and performance of the required clinical trials.
“Lung infections with antibiotic-resistant bacteria are a clinical problem of increasing relevance. We hope to be able to help patients by means of phage-based therapies in the future,” says Witzenrath. The clinical trial will be conducted in the research unit of Charité Research Organisation GmbH (CRO). Furthermore, CRO will provide organizational and regulatory assistance for the entire project, will keep close contact with supervisory drug agencies, and will take care of data management, statistics, and preparation of the clinical study report.
Dr. Andreas Hüser, senior project manager: “Charité Research Organisation has specialized in such studies and we are were excited to be part of this important project. The combination of partners in this project is truly outstanding.”
Dr. Holger Ziehr
Phone +49 531 6181-6001
Dr. Cathrin Nastevska
Phone +49 511 5350-225
For further information and an image, please refer to:
Further scientific contacts:
Leibniz Institute DSMZ – German Collection of Microorganisms and Cell Cultures
Dr. Christine Rohde (Bioeconomics and Health, Working Group on Phages)
Phone +49 531 2616-220
Charité – Universitätsmedizin Berlin
Prof. Dr. Martin Witzenrath (Medical Dep., Division of Infectiology and Pneumonology)
Phone +49 30 450553122
Charité Research Organisation GmbH
Dr. Andreas Hüser (Project manager)
Phone +49 30 450539231
Short profiles of the project partners:
Leibniz Institute DSMZ
With over 50,000 cultures of a broad range of microorganisms and cell lines, Leibniz Institute DSMZ is one of the largest bioresource centers worldwide. Its newly founded Department of Bioeconomics and Health is committed to enhancing the phage collection and is working on a variety of research projects on phages.
The Fraunhofer ITEM Division of Pharmaceutical Biotechnology develops processes for biotechnological agents, with a focus on pharmaceutical applications. For over 20 years, active ingredients from a broad range of substance classes have been manufactured for clinical trials in the division’s laboratories.
Charité – Universitätsmedizin Berlin
Charité’s Medical Department, Division of Infectiology and Pneumonology is intensely dedicated to basic research, besides university-based healthcare and education. The working group headed by Professor Martin Witzenrath is exploring rational foundations for novel therapeutic perspectives and has specialized in translational evaluation of novel therapies. One of its numerous cooperation partners is Leibniz Institute DSMZ. For several years already, the two institutions have collaboratively studied the processes taking place during treatment of bacterial infections with phages.
Charité Research Organisation, Berlin (CRO)
CRO is a wholly-owned subsidiary of Charité – Universitätsmedizin Berlin. The contract research organization is specialized in scientifically demanding and complex phase-I and phase-II trials, which CRO has conducted in its own research unit for over 10 years.
Fraunhofer ITEM Dr. Cathrin Nastevska | Fraunhofer-Gesellschaft
22.02.2018 | Albert-Ludwigs-Universität Freiburg im Breisgau
Separate brain systems cooperate during learning, study finds
22.02.2018 | Brown University
Quantum computers may one day solve algorithmic problems which even the biggest supercomputers today can’t manage. But how do you test a quantum computer to...
For the first time, a team of researchers at the Max-Planck Institute (MPI) for Polymer Research in Mainz, Germany, has succeeded in making an integrated circuit (IC) from just a monolayer of a semiconducting polymer via a bottom-up, self-assembly approach.
In the self-assembly process, the semiconducting polymer arranges itself into an ordered monolayer in a transistor. The transistors are binary switches used...
Breakthrough provides a new concept of the design of molecular motors, sensors and electricity generators at nanoscale
Researchers from the Institute of Organic Chemistry and Biochemistry of the CAS (IOCB Prague), Institute of Physics of the CAS (IP CAS) and Palacký University...
For photographers and scientists, lenses are lifesavers. They reflect and refract light, making possible the imaging systems that drive discovery through the microscope and preserve history through cameras.
But today's glass-based lenses are bulky and resist miniaturization. Next-generation technologies, such as ultrathin cameras or tiny microscopes, require...
Scientists from the University of Zurich have succeeded for the first time in tracking individual stem cells and their neuronal progeny over months within the intact adult brain. This study sheds light on how new neurons are produced throughout life.
The generation of new nerve cells was once thought to taper off at the end of embryonic development. However, recent research has shown that the adult brain...
15.02.2018 | Event News
13.02.2018 | Event News
12.02.2018 | Event News
22.02.2018 | Life Sciences
22.02.2018 | Physics and Astronomy
22.02.2018 | Earth Sciences